"Relay Therapeutics is a clinical-stage precision drug company using its Dynamo platform to design protein-motion-based oncology drugs, led by PI3Kα inhibitor zovegalisib. Shares are up 50.35% year to date and 286.63% over the past year, with a balance sheet showing $554.52 million in cash and investments, supporting runway into 2029. The bull case includes 12 buy ratings and an FDA Breakthrough Therapy designation for zovegalisib."
"Erasca is a precision oncology biotech targeting the RAS/MAPK pathway with pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitors. The company is positioned to capitalize on significant clinical milestones and has garnered analyst support, making it a compelling investment opportunity in the biotech sector."
Clinical-stage biotech companies with share prices under $30 can experience dramatic re-ratings due to pivotal Phase 3 readouts or FDA decisions. Retail investors focus on pipeline quality, cash runway, and analyst support rather than valuation multiples. Three well-rated biotechs under $30 show strong fundamentals, including Relay Therapeutics, which has a promising drug pipeline and significant analyst backing. The company has a solid cash position and is entering a critical period with multiple clinical milestones expected in 2026.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]